Genetic susceptibility is associated with an increased risk of breast cancer. The most common causative gene of hereditary breast cancer is *BRCA1/2*, accounting for almost one quarter of familial breast cancer. In a study of a Korean population, the prevalence of the *BRCA* mutation was reported to be 20% in breast cancer patients with a family history of breast cancer, consistent with Western populations. The estimated cumulative risk of breast and ovarian cancer with *BRCA* mutations have been calculated, respectively, as 72% and 25% for *BRCA1* and 66% and 11% for *BRCA2* \[[@B1]\]. *BRCA* gene testing is supported by National Health Insurance in Korea if the patient has a risk of hereditary breast and ovarian cancer (HBOC). If the patient has been proven to have a *BRCA* mutation, a risk-reducing salpingo-oophorectomy (RRSO) and genetic testing of family members are also supported. There have been several events that drew public attention to HBOC in Korea. First, the Korean Hereditary Breast Cancer Study (KOHBRA study) was started in 2007 \[[@B2]\], with support from the Ministry of Health, and Welfare of Korea and the Korean Breast Cancer Society. Second, the strategy of *BRCA* testing coverage by the National Health Insurance system was promoted in May 2012. Subsequently, Angelina Jolie, an actress from the United States, publicized her story of having a *BRCA1* mutation and her experience of undergoing bilateral risk-reducing mastectomy in May 2013. After her announcement, public awareness of breast cancer susceptibility genes and familial cancer increased, the so-called "Angelina effect" \[[@B3][@B4]\]. We conducted a survey to investigate the influence of the "Angelina effect" on practice patterns for HBOC in Korea and also reviewed national data of *BRCA* gene test prescription. Ethical approval was obtained from institutional review board (number: 2016-04-007). Statistical analysis was performed using SPSS version 21.0 (IBM Corp., Armonk, USA). A *p*-value of \<0.05 was considered statistically significant.

The questionnaire consisted of 38 questions asking participants to recall medical services performed before and after the announcement. A total of 70 participants replied to the questionnaire, most of whom were surgical oncologists. Recommendations of genetic testing were significantly increased in circumstances that might be related to HBOC. Regarding carrier management, magnetic resonance imaging (MRI) or surveillance and tamoxifen for chemoprevention were more frequently recommended (*p*\<0.001). Recommendations of risk-reducing surgeries were also significantly increased. Genetic testing of family members was more commonly recommended when a pathogenic mutation was found (81.4% before the announcement and 98.6% after the announcement, *p*\<0.001). Most of the respondents did not prescribe genetic testing for other genes, but some of the respondents replied that they test for *PTEN* (2.9%) and *TP53* (1.4%), and panel testing was added by 8.6% of physicians.

Another survey regarding institutional records of *BRCA* mutation carriers was available from 28 medical centers. In unaffected carriers, bilateral risk-reducing mastectomy (RRM) was performed in one individual in 2012 before the announcement and another one was performed during 2015 ([Table 1](#T1){ref-type="table"}). In affected carriers, contralateral prophylactic mastectomy increased from four cases per year in 2012 to 20 cases per year in 2015. A significant increase of RRSOs was also seen (16 in 2012 and 75 in 2015, *p*=0.002).

The number of patients who received *BRCA* gene testing from January 2010 to December 2015 was reviewed using the National Health Insurance Review and Assessment Service database ([Figure 1A](#F1){ref-type="fig"}). The annual breast cancer incidence from the Cancer Registry was used as reference, available from 2010 to 2013 \[[@B5]\]. Monthly *BRCA* gene testing prescription was divided into three phases: phase 1 from January 2010 to May 2012 (insurance coverage), phase 2 from June 2012 to May 2013 (Angelina Jolie\'s announcement), and phase 3 from June 2013 to December 2015. The number of patients undergoing *BRCA1* and *BRCA2* testing significantly increased through time. Monthly aggregates of the number of genetic tests was increased in phase 2 (after health insurance coverage) and phase 3 (Angelina Jolie\'s announcement) compared with reference phase 1 (*p*\<0.001 for both phase 2 and phase 3). Phase 3 also showed a significant change compared with phases 1 and 2 (β~year~=33.6 \[3.4\], *p*\<0.001 and βevent=34.9 \[11.9\], *p*=0.005).

The increasing rate of *BRCA1/2* testing is shown in [Table 2](#T2){ref-type="table"}, which also shows a higher rate in major cities than in provincial areas (*p*=0.002). The number of tests increased yearly regardless of the level of care ([Figure 1B](#F1){ref-type="fig"}). In 2012, *BRCA1* genetic testing started to be performed by primary physicians. The cumulative numbers of *BRCA1/2* tests according to age group showed a higher incidence in age groups 30 to 39 and 40 to 49 ([Figure 2](#F2){ref-type="fig"}).

During the period of 2010 to 2013 when the annual breast cancer incidence was available for evaluation, prescription of *BRCA1* testing increased annually, but the increase was statistically nonsignificant (relative risk, 1.341; 95% confidence interval, 1.163--1.546; *p*=0.056). After adjusting for the annual breast cancer incidence rate, male patients more frequently chose genetic testing than female patients, under the assumption that all patients receiving *BRCA* genetic testing were breast cancer patients ([Table 2](#T2){ref-type="table"}).

This study showed that there were positive changes in the practice patterns for HBOC, such as more genetic testing recommendations and more accepting attitudes toward cancer surveillance and chemoprevention, after Angelina Jolie\'s announcement. Although genetic testing for *BRCA* mutations increased annually, it was statistically nonsignificant after correction for an increasing incidence of breast cancer, with a hypothesis that limited information after 2013 might have affected the evaluation. The prevalence of *BRCA2* mutation in Korean male breast cancer was 8.3% in the KOHBRA study \[[@B2]\] compared to other studies reporting prevalence ranging from 3% to 33% \[[@B6][@B7]\]. After adjusting for annual incidence, a higher proportion of male patients than female patients received genetic testing in this study, suggesting an increased risk perception in male patients.

A celebrity\'s medical history can be conveyed to the public and thus increase awareness of a disease \[[@B8]\]. After the New York Times announcement about Angelina Jolie\'s experience, the impact from the article brought global understanding of how a familial history of cancer can be related to personal cancer risk. The "Angelina effect" was seen in increased referrals to genetics services \[[@B9][@B10][@B11]\]. Risk-reducing surgeries were increased after her disclosure \[[@B12]\], and a report of a single institution revealed that 74% of the patients who underwent RRM in 2013 had received their test results more than 18 months previously, indicating that their decision to undergo surgery had been influenced by the announcement \[[@B13]\]. The results of the present study were consistent with those of the other studies, although there was a limitation that the number of risk-reducing surgeries was determined simply by comparing yearly records between 2012 and 2015.

We previously reported the effect of the KOHBRA study on HBOC management in 2009 \[[@B14]\]. Before the study (2007), 8% of physicians recommended MRI compared with 10% after the study (2009), whereas 60% of the physicians (2015) in the present study recommended MRI. There was no significant difference in the number of RRMs performed. On the other hand, RRSO was performed in 27 cases in 25 institutions in 2009 and in 75 cases in 27 institutions (the participating institutions were not the same) in 2015. Some physicians responding to our survey mentioned that patients are reluctant to undergo contralateral prophylactic mastectomy or RRM, and therefore the decision tends to be made based on the patient\'s wishes rather than their actual risks.

Genetic testing recommendations by physicians and the numbers of *BRCA* tests have been increasing not only because of Angelina Jolie\'s announcement changing the public\'s perception but also because of the insurance coverage. RRM in unaffected carriers has not yet been widely performed. Information from further investigation of cancer risk in unaffected mutation carriers in a Korean population would help future decision-making.
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![Annual trend of *BRCA* gene testing prescription. (A) Annual patient numbers who received *BRCA1* and *BRCA2* genetic testing. (B) Annual *BRCA1* testing numbers by level of care from 2010 to 2015. *p*-value represents for trend test.\
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![Number of *BRCA1* prescription by age group from 2010 to 2015. Age of 30\' in women showed the highest testing rate.](jbc-20-203-g002){#F2}

###### Acceptance of risk-reducing surgery in *BRCA1/2* mutation carriers

![](jbc-20-203-i001)

  ----------------------------------------------------------------------------------------------------
                                          Before announcement\   After announcement\   *p*-value^\*^
                                          (2012)                 (2015)                
  --------------------------------------- ---------------------- --------------------- ---------------
  Bilateral risk-reducing mastectomy      1                      1                     1.000

  Contralateral prophylactic mastectomy   4                      20                    0.017

  Risk-reducing salpingo-oophorectomy                                                  

   Unaffected carrier                     1                      2                     0.317

   Affected carrier                       16                     75                    0.002
  ----------------------------------------------------------------------------------------------------

^\*^*p*-value by Wilcoxon\'s signed rank test.

###### *BRCA1* testing prescription rate following patient factors and annual breast cancer incidence rate (2010--2013)

![](jbc-20-203-i002)

                      β           SE        *p*-value^\*^   RR      95% CI   *p*-value^†^   
  ------------------- ----------- --------- --------------- ------- -------- -------------- ---------
  Model 1^‡^                                                                                
   *BRCA1* testing    468.743     63.327    0.002           1.341   1.163    1.546          0.056
  Model 2^§^                                                                                
   *BRCA1* testing    117.321     37.11     0.005           1.342   1.247    1.444          \<0.001
   Sex                                      \<0.001                                         0.019
    Male              Reference             Reference                                       
    Female            701.083     126.753   0.361           0.172   0.757                   
   Patients                                 0.024                                           \<0.001
    Inpatient         Reference             0.35            0.293   0.418                   
    Outpatient        --310.250   126.753   Reference                                       
  Model 3^§^                                                                                
   *BRCA1* testing    234.657     51.137    0.001           \-      \-       \-             \-
   Area                                     0.002                                           
    Urban cities      Reference             \-              \-      \-       \-             
    Provincial area   --751.333   174.668   \-              \-      \-       \-             

SE=standard error; RR=relative risk; CI=confidence interval.

^\*^*p*-value by Linear regression analysis without adjustment by annual breast cancer incidence; ^†^*p*-value by Poisson regression analysis with adjustment by annual breast cancer incidence; ^‡^model observing serial change; ^§^model observing serial change adjusted by multiple factors.
